Trial Profile
A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcutaneously in Patients With Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs CC 90006 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 06 May 2020 Status changed from recruiting to completed.
- 18 May 2018 Planned End Date changed from 1 Jun 2019 to 30 Aug 2019.
- 18 May 2018 Planned primary completion date changed from 1 Jun 2019 to 30 Aug 2019.